Which Pharma Product Websites are Driving Consumers to the Doctor to Request Prescriptions?

Manhattan ResearchPharmaceutical and healthcare market research company Manhattan Research recently released the ePharma Consumer® v10.0 study, which explores the online behaviors of ePharma Consumers, or U.S. consumers using the Internet for prescription drug information. The study also provides in-depth metrics for hundreds of pharma product websites, including satisfaction, reasons for visiting, and post-visitation actions, as well as adoption and interest for various types of online resources and services from pharma.

The study found that pharma product websites are effective at driving post-visitation action. 74%* of ePharma Consumers visiting these websites take a product-related action afterward - either discussing product info with their doctor, family or friends; requesting or filling the prescription; or searching for more product info online.

Among the more than 320 pharma product websites tracked in the study, the brand website of erectile dysfunction treatment Levitra® was the most likely to drive visitors to request a prescription for the drug from their doctor. The brand websites for Chantix®, Cialis®, Nexium®, and Yaz® round out the top five most likely to drive visitors to request prescriptions.

A common theme among top websites is content and structure designed to lead consumers to talk to their doctor. Additionally, many of these products, such as the sleep aid Lunesta® and the acid reflux treatment Nexium®, feature doctor discussion guides or worksheets on their websites.

Top Pharma Product Websites Driving Visitors to Request that Prescription from the Doctor

1. Levitra®
2. Chantix®
3. Cialis®
4. Nexium®
5. Yaz®
6. Lyrica®
7. NuvaRing®
8. Symbicort®
9. Viagra®
10. Lunesta®

Websites with the highest percent of visitors responding that they "requested a prescription for this product from a doctor" after visiting website for themselves; Among U.S. adults ages 18+ online for pharma information and websites for which n>60

* Industry average of aided responses across more than 320 product websites visited

Complimentary ePharma Consumer® Data Snapshot
If you'd like to download a complimentary one-page snapshot of data and insights from the ePharma Consumer® v10.0 study, please visit http://www.manhattanresearch.com/research/data-snapshots/epharma-consumer-data-snapshot.aspx.

About ePharma Consumer® v10.0
ePharma Consumer® v10.0 was fielded online in Q4 2010 among 6,606 U.S. adults (ages 18+) who have gone online for pharma or prescription drug information in the past 12 months. This study also explores demand for adherence tools and services and the extent to which consumers leverage the Internet to lower drug spending. The study also provides key metrics for hundreds of pharma product websites.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a global pharmaceutical and healthcare market research and strategic advisory firm and conducts annual research studies covering eHealth trends among healthcare professionals and consumers.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...